CADL
What one share of Candel Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Our engineered viruses are designed to induce a systemic anti-tumor response due to induction of immunogenic cell death within the tumor microenvironment, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection.
Candel Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.47 |
|---|---|
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$0.95 |
| Cash and investments | $2.65 |
| Debt | $0.61 |
| Book value | $1.66 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.01 | −$1.52 | $0.13 | −$0.91 | — | −$2.03 |
| 2021 | $0.01 | −$1.91 | $0.10 | −$1.27 | — | $2.24 |
| 2022 | $0.00 | −$0.65 | $0.04 | −$1.14 | — | $1.65 |
| 2023 | — | −$1.31 | $0.02 | −$1.20 | — | $0.44 |
| 2024 | — | −$1.74 | $0.00 | −$0.85 | — | $1.42 |
| 2025 | — | −$0.72 | $0.01 | −$0.73 | — | $0.95 |